Clinically, a recent meta-analysis of over 100,000 cancer patients and survivors showed that SGLT2i use reduced HF hospitalizations by 51% (RR 0.49, 95% CI 0.36–0.66, I2 = 28%, p < 0.01) and new HF diagnoses by 71% (RR 0.29, 95% CI 0.10–0.87) and MyD88-dependent signaling, which are critical drivers of cardiac inflammation and fibrosis. The gene discussed is MYD88; the disease is cancer.